Screener / SEC EDGAR /CIK 0000313143 /10-K filed May 20, 2026, compared with May 21, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Haemonetics Corp HAE

Compare with peers Embed
Planned sales, announced before they happen

0 trading plans running, 1 Form 144 notice for $101K

10-Q, 10-K and Form 144

What HAE's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From May 30, 2023 to Nov 16, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Stewart W. Strong
President, Global Hospital
Adopted 10b5-1 plan Feb 14, 2025 10-K May 21, 2025
What the company wrote
During the three months ended March 29, 2025, certain of our directors and officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock as follows: Trading Arrangement Name and Title Action Date (1) Rule 10b5-1* Non-Rule 10b5-1** Number of Shares to be Sold (2) Expiration Date (3) Stewart W. Strong, President, Global Hospital Adoption 2/14/2025 X 11,997 (4) 6/13/2025 * Intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. ** Not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. (1) Reflects the fully-executed date of each trading arrangement, which may differ from the date of first execution by an officer or director. (2) The number of shares of common stock sold under each trading arrangement, if any, will be net of shares withheld for applicable tax obligations upon the vesting and/or exercise of covered securities as well as for payment of the exercise price upon the exercise of stock options, which amounts are not yet determinable. (3) Except as otherwise indicated by footnote, each trading arrangement expires upon the earlier of (a) completion of all authorized transactions thereunder and (b) the expiration date listed above. (4) Includes 8,246 target shares subject to a performance share unit (“PSU”) award previously granted to Mr. Strong on May 16, 2022. The actual number of shares to be earned under the PSU award, and subject to sale under this trading arrangement, may range from 0% to a maximum of 200% of the target award depending upon the Company’s total shareholder return relative to the components of the S&P MidCap 400 index during a three-year performance period from May 16, 2022 to May 15, 2025.
Josep L. Llorens
EVP, Global Manufacturing and Supply Chain
Adopted 10b5-1 plan Jun 12, 2024 10-Q Aug 8, 2024
What the company wrote
During the three months ended June 29, 2024, certain of our directors and officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock as follows: Trading Arrangement Name and Title Action Date (1) Rule 10b5-1* Non-Rule 10b5-1** Number of Shares to be Sold (2) Expiration Date (3) Josep L. Llorens, EVP, Global Manufacturing and Supply Chain Adoption 6/12/2024 X 14,314 7/11/2025 * Intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. ** Not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. (1) Reflects the fully-executed date of each trading arrangement, which may differ from the date of first execution by an officer or director. (2) The number of shares of common stock sold under each trading arrangement, if any, will be net of shares withheld for applicable tax obligations upon the vesting and/or exercise of covered securities as well as for payment of the exercise price upon the exercise of stock options, which amounts are not yet determinable. (3) Except as otherwise indicated by footnote, each trading arrangement expires upon the earlier of (a) completion of all authorized transactions thereunder and (b) the expiration date listed above.
Anila Lingamneni
EVP, Chief Technology Officer
Adopted 10b5-1 plan Mar 13, 2024 10-K May 20, 2024
What the company wrote
During the three months ended March 30, 2024, certain of our directors and officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock as follows: Trading Arrangement Name and Title Action Date (1) Rule 10b5-1* Non-Rule 10b5-1** Number of Shares to be Sold (2) Expiration Date (3) Anila Lingamneni, EVP, Chief Technology Officer Adoption 3/13/2024 X 11,679 (4) 5/30/2025 * Intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. ** Not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. (1) Reflects the fully-executed date of each trading arrangement, which may differ from the date of first execution by an officer or director. (2) The number of shares of common stock sold under each trading arrangement, if any, will be net of shares withheld for applicable tax obligations upon the vesting and/or exercise of covered securities as well as for payment of the exercise price upon the exercise of stock options, which amounts are not yet determinable. (3) Except as otherwise indicated by footnote, each trading arrangement expires upon the earlier of (a) completion of all authorized transactions thereunder and (b) the expiration date listed above. (4) Includes 7,070 target shares subject to a performance share unit (“PSU”) award previously granted to Ms. Lingamneni on May 18, 2021. The actual number of shares to be earned under the PSU award, and subject to sale under this trading arrangement, may range from 0% to a maximum of 200% of the target award depending upon the Company’s total shareholder return relative to the components of the S&P MidCap 400 index during a three-year performance period from May 18, 2021 to May 17, 2024.
Michelle L. Basil
EVP, General Counsel
Adopted plan Dec 14, 2023 10-Q Feb 8, 2024
What the company wrote
During the three months ended December 30, 2023, certain of our directors and officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock as follows: Trading Arrangement Name and Title Action Date (1) Rule 10b5-1* Non-Rule 10b5-1** Number of Shares to be Sold (2) Expiration Date (3) Michelle L. Basil, EVP, General Counsel Adoption 12/14/2023 X 17,567 (4) 8/15/2024 * Intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. ** Not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. (1) Reflects the fully-executed date of each trading arrangement, which may differ from the date of first execution by an officer or director. (2) The number of shares of common stock sold under each trading arrangement, if any, will be net of shares withheld for applicable tax obligations upon the vesting and/or exercise of covered securities as well as for payment of the exercise price upon the exercise of stock options, which amounts are not yet determinable. (3) Except as otherwise indicated by footnote, each trading arrangement expires upon the earlier of (a) completion of all authorized transactions thereunder and (b) the expiration date listed above. (4) Includes 12,374 shares subject to a performance share unit (“PSU”) award previously granted to Ms. Basil on May 18, 2021. The actual number of shares to be earned under the PSU award, and subject to sale under this trading arrangement, may range from 0% to a maximum of 200% of the target award depending upon the Company’s total shareholder return relative to the components of the S&P MidCap 400 index during a three-year performance period from May 18, 2021 to May 17, 2024.
Josep Llorens
EVP, Global Manufacturing and Supply Chain
Adopted plan Aug 31, 2023 10-Q Nov 2, 2023
Stewart Strong
President, Global Hospital
Adopted plan Jun 12, 2023 10-Q Aug 8, 2023
Anila Lingamneni
EVP, Chief Technology Officer
Adopted plan Jun 5, 2023 10-Q Aug 8, 2023
Charles Dockendorff
Director
Adopted plan May 30, 2023 10-Q Aug 8, 2023

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 22, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

FiledSellerSharesValue
Nov 12, 2026 Maunsell Farris Maryanne
Officer
836 $101K

From the Form 144 XML filed with the SEC, since Nov 12, 2026. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HAE/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.